WO2007120838A2 - Rapidly disintegrating solid oral dosage form of liquid dispersions - Google Patents
Rapidly disintegrating solid oral dosage form of liquid dispersions Download PDFInfo
- Publication number
- WO2007120838A2 WO2007120838A2 PCT/US2007/009159 US2007009159W WO2007120838A2 WO 2007120838 A2 WO2007120838 A2 WO 2007120838A2 US 2007009159 W US2007009159 W US 2007009159W WO 2007120838 A2 WO2007120838 A2 WO 2007120838A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agent
- active agent
- rapidly disintegrating
- volume reduction
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 title claims description 42
- 239000006185 dispersion Substances 0.000 title claims description 18
- 239000006186 oral dosage form Substances 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000013543 active substance Substances 0.000 claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 31
- 239000002245 particle Substances 0.000 claims description 28
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 239000002552 dosage form Substances 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 9
- -1 polyoxyethylene copolymers Polymers 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000007891 compressed tablet Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009477 fluid bed granulation Methods 0.000 claims description 3
- 238000009478 high shear granulation Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229920003174 cellulose-based polymer Polymers 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229940001470 psychoactive drug Drugs 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 238000007781 pre-processing Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 22
- 239000000463 material Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 6
- 229940039227 diagnostic agent Drugs 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960000913 crospovidone Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- 229960003305 alfaxalone Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
- 229950011530 anipamil Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AINMMCNEBFCEJY-UHFFFAOYSA-N calcium magnesium silicic acid silicate Chemical compound [Mg+2].[Ca+2].O[Si](O)(O)O.O[Si](O)(O)O.[O-][Si]([O-])([O-])[O-] AINMMCNEBFCEJY-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- IQDXNHZDRQHKEF-UHFFFAOYSA-N dialuminum;dicalcium;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[Ca+2].[Ca+2].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O IQDXNHZDRQHKEF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004041 inotropic agent Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- Rapidly disintegrating solid oral dosage forms which comprise an active ingredient and at least one pharmaceutically acceptable liquid volume reduction agent wherein the liquid volume reduction agent comprises from about 10% to about 90% w/w of the composition.
- Methods for preparing and using said dosage forms are also presented.
- Rapidly disintegrating dosage forms are known in the art. See for example, U.S.
- Pat. No. 5,607,697 which describes a solid dosage form consisting of coated microparticles that disintegrate in the mouth.
- the microparticle core has a pharmaceutical agent and the core is coated with a material that retards dissolution in the mouth and masks the taste of the pharmaceutical agent.
- the microparticles are then compressed to form a tablet.
- Other excipients can also be added to the tablet formulation. See also, U.S.
- Other publications include: 5,871,781; 5,869,098; 5,866,163; 5,851,553; 5,622,719; 5,567,439; 5,587,172;
- Novel rapidly disintegrating solid dose oral formulations of liquid dispersions of active agents are presented. These formulations provide easy dosage form administration and consumer convenience and compliance, fast onset of therapeutic activity combined with substantially complete disintegration of the formulation in less than about one minute.
- a method of preparing rapidly disintegrating solid dose oral formulations comprises: (1) providing a liquid dispersion of an active agent; (2) adding at least one pharmaceutically acceptable liquid volume reduction agent; (3) forming a semi-solid viscous composition; and (4) forming rapidly disintegrating particles.
- the methods further comprise processing the rapidly disintegrating particles into rapidly disintegrating dosage forms such as powders, granules, tablets, etc. suitable for oral administration. Additional pharmaceutically acceptable excipients can also be added to the composition for administration.
- Yet another aspect of the present invention provides a method of treating a mammal, including a human, requiring rapid onset of therapeutic activity with a rapidly disintegrating composition of the invention.
- substantially all asperities includes groups of all asperities and groups of all asperities minus a relatively small portion of asperities.
- the term "about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above” or "a little below” the endpoint.
- Rapidly disintegrating dosage forms disintegrate or disperse rapidly in a biological medium such as water, saliva, tears, vaginal fluids, or plasma or on the skin or mucosal surface.
- a biological medium such as water, saliva, tears, vaginal fluids, or plasma or on the skin or mucosal surface.
- Rapidly dissolving dosage forms can be beneficial because of their ease of administration and convenience.
- the rapidly disintegrating formulations of the invention comprise an active agent to be administered, at least one liquid volume reduction agent from about.15% to about 90% by weight, and optionally other pharmaceutically acceptable excipients such as diluents, lubricants, binders, disintegrants, flavorants, colorants, etc.
- the active agent can be in a crystalline form, semi-crystalline form, amorphous form, or a combination thereof.
- the active agent may be a poorly soluble drug or a fairly soluble drug.
- a rapidly disintegrating solid oral dosage form according to the invention has a disintegration time of less than about 1 minute upon addition to an aqueous medium. More preferably, the dosage form has a disintegration time upon addition to an aqueous medium of less than about 45 seconds, less than about 30 seconds, less than about 20 seconds, less than about 15 seconds, less than about 10 seconds, or less than about 5 seconds.
- the rapidly disintegrating solid dose compositions can be formulated to mask the unpleasant taste of an active agent.
- Such taste masking can be accomplished, for example, by the addition of one or more sweet tasting excipients, by coating the active agent with a sweet tasting excipient, and/or by coating a dosage form of the active agent, and excipients with a sweet tasting excipient.
- the rapidly disintegrating solid oral dosage forms may also comprise nanoparticulate or nanoemulsion dispersions.
- nanoparticulate compositions first described in U.S. Pat. No. 5,145,684 ("the '684 patent"), may consist of a particles of poorly soluble active agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer.
- the '684 patent also describes methods of making such nanoparticulate compositions, which is incorporated by reference herein.
- Other publications relating to nanoparticulate compositions include: U.S. Pat. Nos.
- the invention can be practiced with a wide variety of active agents or diagnostic agents.
- the drug or diagnostic agent is preferably present in an essentially pure form, is either fairly or poorly water soluble, and is dispersible in at least one liquid medium.
- fairly water soluble it is meant that the drug or diagnostic agent has a solubility in water of greater than 30mg/ml.
- poorly water soluble it is meant that the drug or diagnostic - S - agent has a solubility in water of less than about 30 mg/ml, preferably less than about 10 mg/ml and more preferably less than about 1 mg/ml.
- the active agent can be selected from a variety of known classes of drugs or diagnostic agents, including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillin's), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics,
- the drugs or diagnostic agents are commercially available and/or can be prepared by techniques known in the art.
- the active ingredient may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers.
- Non-limiting examples of representative poorly water soluble drugs or fairley water soluble drugs include: albendazole alfaxalone, acyclovir, alprostadil, aminofostin, anipamil, azido thymidine, beciomethasone, belomycin, bromocriptine, busulfan, captopril, carbamazepine, cefalexin, cefluoroxime, clonidine, corticosterone, Cortisol, cyclophosphamide, cyclosporin A, and other cyclosporins, desogestrel, dexarnethasone, dideoxyadenosine, doxorubicin, econazole, epoprostenol, estradiol, etoposide, felbamate, glipizide, griseofulvin, ketoconazole, metronidazole, nifedipine, oxytetracycline, piroxicam, predn
- compositions of the present invention comprise from about 15% to about 90% by weight of a liquid volume reduction agent.
- the active agent is initially presented in a liquid as dispersion.
- the dispersion may include a suspension or a solution and the like.
- the liquid may be any pharmaceutically acceptable liquid such as water, alcohol, propylene glycol, glycerin, polyethylene glycol, sorbitol, among others.
- the liquid volume reduction agent operates to reduce the volume of the liquid dispersion comprising the active agent thereby providing a semi-solid viscous dispersion which is further processed into a solid oral rapidly disintegrating dosage form for administration.
- the amount of the liquid volume reduction agent may range from: about 10% to about 20%; about 15% to about 30%; about 15% to about 40%; about 20% to about 40%; about 15% to about 50%; about 15% to about 60%; about 15% to about 70%; about 15% to about 80%; about 20% to about 50%; about 20% to about 60%; about 20% to about
- the liquid volume reduction agent is any material that reduces the volume of the liquid in the liquid dispersion comprising the active agent.
- Some non-limiting examples include: methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, silicon dioxide, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and the like.
- polyethylene glycol polyethylene glycol,polyoxyethylene, carbomers and cellulose-based polymers
- crospovidone silicified microcrystalline cellulose
- mannitol mannitol
- croscarmellose microcrystalline cellulose
- calcium silicate calcium salts such as calcium phosphate, calcium carbonate, calcium magnesium trisilicate, calcium aluminum silicate, etc.
- the liquid dispersion may originally contain for example solids of about 10% or 20% or 30% or 50% or 60% or 70% or 80%.
- This dispersion is then contacted with a liquid volume reduction agent which facilitates the formation of a semi-solid composition by reducing the weight percentage or volume of the liquid phase.
- the liquid volume reduction agent for example may reduce the liquid phase of the composition by about 10%, or 20%, or 30%, or 40% or 50% or 60% or 70% or 80% or 90% either by weight or by volume.
- This semi-solid composition is then subjected to processes described herein such as fluid bed drying, spray congealing, fluid bed granulation, high shear granulation or forming into a suitable dosage form.
- processes described herein such as fluid bed drying, spray congealing, fluid bed granulation, high shear granulation or forming into a suitable dosage form.
- compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
- excipients are known in the art.
- the active agent composition can be present in the rapidly disintegrating formulations of the invention in an amount of about 0.1% to about 99.9/(w/w), preferably about 5% to about 70% (w/w), and most preferably about 15% to about 40% (w/w), based on the total weight of the dry composition.
- a rapidly disintegrating solid oral dosage form of the invention can be prepared by granulating in a fluidized bed an admixture comprising a liquid dispersion of active agent and at least one liquid volume reduction agent and optionally suitable excipients to form a granulate. This is followed by tableting of the granulate to form a solid oral dosage form.
- Granulation of the composition can be accomplished using a fluid bed granulator or by using high shear granulation. Fluid bed drying can also be used in making dry powder for processing into a dosage formulation.
- Powders for tableting can be formulated into tablets by any method known in the art. Suitable methods include, but are not limited to, milling, fluid bed granulation, dry granulation, direct compression, spheronization, spray congealing, and spray-dying.
- a rapidly disintegrating dosage form can be prepared by blending a nanoparticulate composition, comprising a poorly soluble active agent and at least one surface stabilizer, with at least one pharmaceutically acceptable water-soluble or water- dispersible excipient, and, optionally, other excipients to form a blend which is then directly compressed into tablets.
- spray-dried nanoparticulate powder can be blended with tablet excipients using a V -blender, or high-shear mixer, followed by compression of the powder using, for example, an automated press, single station Korsch press, or a high-speed Fette tablet press.
- the rapidly disintegrating compositions of the present invention comprise an active agent whose particle size has remained substantially the same as compared to the particle size of the active agent in the liquid dispersion prior to the addition of liquid volume reduction agent in the manufacturing process.
- the rapidly disintegrating compositions of the present invention comprise active agent whose particle size is substantially preserved in the final dosage form.
- the phrases "substantially preserved” or “remained substantially the same” refer to the situation in which the particle size distribution remains within a 10-20% deviation.
- the particle size distribution is measured and or represented as a mean particle diameter of a certain % of the particles.
- Substantial preservation of particle size in the composition is significant because particle size of the active agent plays a critical role for many pharmaceutical products. For example, particle size changes may affect flow properties, dissolution, and absorption among others.
- the present invention provides a method to prepare a rapidly disintegrating composition of an active agent without substantially changing the particle size of the active agent comprising the steps of: a) preparing a liquid dispersion of said active agent; b) adding at least one pharmaceutically acceptable liquid volume reduction agent to said liquid dispersion; c) forming a semi-solid viscous composition; and d) forming rapidly disintegrating particles; and e) optionally compressing said particles into a rapidly disintegrating tablet.
- the rapidly disintegrating particles are formed from the semi-solid viscous composition by way of freeze-drying.
- the technique for freeze-drying is generally known in the art.
- the particles may be formed by vaccum drying.
- vaccum drying and freeze-drying techniques should be employed where no damage to or degradation of the active agent is known to occur.
- Another possible technique is by way of filtration. Commonly used filtering materials may be employed. Again, in all these cases, particle size of the active agent is substantially preserved.
- the rapidly disintegrating solid formulations of the invention can be in the form of tablets for oral administration. Preparation of such tablets can be by pharmaceutical compression or molding techniques known in the art.
- the tablets of the invention may take any appropriate shape, such as discoid, round, oval, oblong, cylindrical, triangular, hexagonal, and the like.
- the tablets may be coated or uncoated. If coated they may be sugar-coated (to cover objectionable tastes or odors and to protect against oxidation) or film coated (a thin film of water soluble matter for similar purposes).
- the rapidly disintegrating formulations of the invention can be prepared without using a lubricating agent in a substantial amount.
- the rapidly disintegrating tablets may be prepared wherein commonly used lubricants such as magnesium stearate are not substantially present or needed.
- the term "substantially” means "to be effective.”
- the rapidly disintegrating tablets of the present invention may be prepared wherein a lubricating agent such as magnesium stearate is either not present or if present is not in an amount to be effective to perform its intended function.
- the present invention provides a method of treating a mammal including a human, requiring the rapid availability of an active ingredient.
- the administered rapidly disintegrating compositions of the invention rapidly release an incorporated active agent resulting in fast onset of activity.
- the compositions of the invention will be administered orally to a mammalian subject in need thereof using a level of drug or active agent that is sufficient to provide the desired physiological effect.
- the mammalian subject may be a domestic animal or pet but preferably is a human subject.
- the level of drug or active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts.
- EXAMPLE 1 Preparation of a rapidly disintegrating dosage form of Drug A.
- Drug A is a poorly soluble steroidal active agent.
- Crospovidone, mannitol and silicon dioxide each of approximately 14% by weight are used as liquid volume reduction agent. These are blended in a double cone blender until the mixture is uniform.
- Drug A is suspended in water at 28% w/w.
- the liquid volume reduction agent mixture is then slowly added to the Drug A suspension under continuous low shear mixing to form viscous semi-solid composition.
- the material is then cooled to about -50 0 C for about an hour.
- the material is then dried in a freeze drier for about 5-6 hours. Then the material is slowly brought to room temperature. This formed material is then collected in blister packs.
- the formulation disintegrates in about 40 seconds. The disintegration time is measured using both conventional USP apparatus and also using a stop watch and visual observation.
- Example 1 The semi-solid material as described in Example 1 is prepared. The material is then dried as in Example 1. The dried material is then sieved using a sieve of desired size (size #16). The dried sieved material iss then compressed into rapidly disintegrating tablets. The tablets disintegrate in about 30 seconds.
- EXAMPLE 3 The Example 2 above is followed to prepare dried sieved materials. The material is compressed into rapidly disintegrating tablets, but this time without using any lubricating material. The tablets disintegrate in less than 20 seconds.
- EXAMPLE 4 The procedure described in Example 1 is followed with the exception that crospovidone at 15% w/w is used as the liquid volume reduction agent. The formed material disintegrates in about 20 seconds.
- Example 1 is followed except that croscarmellose sodium (about 5%) and silicified MCC (about 21%) are used as liquid volume reduction agents.
- the formed composition disintegrates in about 25 seconds.
- Example 6 composition is used to granulate, using mannitol about 57% as flowability agent and/or disintegrant.
- the compressed tablet disintegrates in about 40 seconds.
- Example 1 procedure is followed, except that the mixture of croscarmellose sodium (about 5%), silicified CMC (about 10%) and mannitol (about 10%) is used as liquid volume reduction agent.
- the formed product disintegrates in about 20 seconds.
- Example 8 material is used further to granulate using about 56% of mannitol as the flowability agent/disintegrant.
- the compressed tablet disintegrates in about 30 seconds.
- a disintegration tester containing 710 micron sieves is used to test tablets in a 1000 ml deionized water bath at 37 C. Disintegration measurements are performed in accordance with USP 20.
- Example 12 The methodology of Example 1 is used to prepare rapidly disintegrating itraconazole preparation. Further, itraconazole is prepared into rapidly disintegrating tablets of 50mg, lOOmg, 200mg and 400mg per unit dose.
- EXAMPLE 12 The methodology of Example 1 is used to prepare rapidly disintegrating itraconazole preparation. Further, itraconazole is prepared into rapidly disintegrating tablets of 50mg, lOOmg, 200mg and 400mg per unit dose.
- Example 6 The methodology of Example 6 is used to prepare rapidly disintegrating paclitaxel preparation.
- Paclitaxel is prepared into tablets of lOmg, 20mg, 50mg, lOOmg and 200mg.
- Example 1 The methodology of Example 1 is used to prepare rapidly disintegrating dexamethasone preparation. Further, dexamethasone is prepared into rapidly disintegrating tablets of lmg, 2mg, 5mg, 10mg, 25mg and 50mg per unit dose.
- Example 7 The methodology of Example 7 is used to prepare rapidly disintegrating acyclovir preparation. Further, acyclovir is prepared into rapidly disintegrating tablets of 50mg, lOOmg, 200mg and 400mg per unit dose.
Abstract
Solid dose rapidly disintegrating compositions for administering pharmaceutical and nutritional supplement agents and methods for the preparation thereof are disclosed and described. Preparation methods which maintain the particulate size of an active agent at the pre-processing size in the final composition are further disclosed. The ability to maintain such particulate size provides a number of advantages, including improved bioavailability and more accurate dosing.
Description
RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM OF
LIQUID DISPERSIONS
PRIORITY DATA This application claims the benefit of United States Provisional Patent Application
Serial No. 60/744,845, filed on April 14, 2006, and United States Non-Provisional Patent Application Serial No. unknown, filed on April 12, 2007, which are incorporated herein by reference.
FIELD OF THE INVENTION
Rapidly disintegrating solid oral dosage forms are disclosed which comprise an active ingredient and at least one pharmaceutically acceptable liquid volume reduction agent wherein the liquid volume reduction agent comprises from about 10% to about 90% w/w of the composition. Methods for preparing and using said dosage forms are also presented.
BACKGROUND OF THE INVENTION
Rapidly disintegrating dosage forms are known in the art. See for example, U.S.
Pat. No. 5,607,697, which describes a solid dosage form consisting of coated microparticles that disintegrate in the mouth. The microparticle core has a pharmaceutical agent and the core is coated with a material that retards dissolution in the mouth and masks the taste of the pharmaceutical agent. The microparticles are then compressed to form a tablet. Other excipients can also be added to the tablet formulation. See also, U.S.
Pat. Nos. 5,503,846, 5,223,264; 5,178,878; 5,401,513; and 5,219,574. Other publications include: 5,871,781; 5,869,098; 5,866,163; 5,851,553; 5,622,719; 5,567,439; 5,587,172;
5,464,632; 4,642,903 5,188,825; 5,631,023; 5,827,541; 5,576,014; 5,446,464; 5,807,576;
5,635,210; 5,595,761; 5,587,180; 5,776,491; 5,639,475; 5,709,886; 5,807,578; 5,807,577;
5,112,616; 5,073,374, which are all incorporated by reference.
SUMMARY OF THE INVENTION
Novel rapidly disintegrating solid dose oral formulations of liquid dispersions of active agents are presented. These formulations provide easy dosage form administration and consumer convenience and compliance, fast onset of therapeutic activity combined with substantially complete disintegration of the formulation in less than about one minute.
In another aspect, there is provided a method of preparing rapidly disintegrating solid dose oral formulations. The method comprises: (1) providing a liquid dispersion of an active agent; (2) adding at least one pharmaceutically acceptable liquid volume reduction agent; (3) forming a semi-solid viscous composition; and (4) forming rapidly disintegrating particles. The methods further comprise processing the rapidly disintegrating particles into rapidly disintegrating dosage forms such as powders, granules, tablets, etc. suitable for oral administration. Additional pharmaceutically acceptable excipients can also be added to the composition for administration. Yet another aspect of the present invention provides a method of treating a mammal, including a human, requiring rapid onset of therapeutic activity with a rapidly disintegrating composition of the invention.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
DETAILED DESCRIPTION OF THE INVENTION Definitions
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set forth below.
The singular forms "a," "an," and, "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a drug" includes reference to one or more of drugs or active agents, and reference to "the carrier" includes reference to one or more of such carriers.
As used herein, "substantially" refers to situations close to and including 100%.
Substantially is used to indicate that, though 100% is desirable, a small deviation therefrom is acceptable. For example, substantially all asperities includes groups of all asperities and groups of all asperities minus a relatively small portion of asperities. As used herein, the term "about" is used to provide flexibility to a numerical range endpoint by providing that a given value may be "a little above" or "a little below" the endpoint.
As used herein, a plurality of items, structural elements, compositional elements, and/or materials may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construed as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of "about 1 to about 5" should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3, and 4 and sub-ranges such as from 1-3, from 2-4, and from 3-5, etc.
This same principle applies to ranges reciting only one numerical value. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described. The Invention
Rapidly disintegrating dosage forms disintegrate or disperse rapidly in a biological medium such as water, saliva, tears, vaginal fluids, or plasma or on the skin or mucosal surface. For example, when the dosage form is administered orally, the dosage form disintegrates or disperses rapidly the patient's mouth without chewing or the need for water within a very short time. Rapidly dissolving dosage forms can be beneficial because of their ease of administration and convenience.
The rapidly disintegrating formulations of the invention comprise an active agent to be administered, at least one liquid volume reduction agent from about.15% to about 90% by weight, and optionally other pharmaceutically acceptable excipients such as diluents, lubricants, binders, disintegrants, flavorants, colorants, etc. The active agent can be in a crystalline form, semi-crystalline form, amorphous form, or a combination thereof. The active agent may be a poorly soluble drug or a fairly soluble drug.
A rapidly disintegrating solid oral dosage form according to the invention has a disintegration time of less than about 1 minute upon addition to an aqueous medium. More preferably, the dosage form has a disintegration time upon addition to an aqueous medium of less than about 45 seconds, less than about 30 seconds, less than about 20 seconds, less than about 15 seconds, less than about 10 seconds, or less than about 5 seconds.
The rapidly disintegrating solid dose compositions can be formulated to mask the unpleasant taste of an active agent. Such taste masking can be accomplished, for example, by the addition of one or more sweet tasting excipients, by coating the active agent with a sweet tasting excipient, and/or by coating a dosage form of the active agent, and excipients with a sweet tasting excipient.
The rapidly disintegrating solid oral dosage forms may also comprise nanoparticulate or nanoemulsion dispersions. For example, nanoparticulate compositions, first described in U.S. Pat. No. 5,145,684 ("the '684 patent"), may consist of a particles of poorly soluble active agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer. The '684 patent also describes methods of making such nanoparticulate compositions, which is incorporated by reference herein. Other publications relating to nanoparticulate compositions include: U.S. Pat. Nos. 5,518,187; 5,862,999; 5,718,388; 5,510,118; 5,318,767; 5,399,363; 5,494,683; 5,429,824; 5,518,738; 5,552,160; 5,747,001, all of which are incorporated by reference herein.
The invention can be practiced with a wide variety of active agents or diagnostic agents. The drug or diagnostic agent is preferably present in an essentially pure form, is either fairly or poorly water soluble, and is dispersible in at least one liquid medium. By "fairly water soluble" it is meant that the drug or diagnostic agent has a solubility in water of greater than 30mg/ml. By "poorly water soluble" it is meant that the drug or diagnostic
- S - agent has a solubility in water of less than about 30 mg/ml, preferably less than about 10 mg/ml and more preferably less than about 1 mg/ml.
The active agent can be selected from a variety of known classes of drugs or diagnostic agents, including, for example, analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillin's), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radiopharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, and xanthines.
The drugs or diagnostic agents are commercially available and/or can be prepared by techniques known in the art. The active ingredient may be present in any amount which is sufficient to elicit a therapeutic effect and, where applicable, may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers.
Non-limiting examples of representative poorly water soluble drugs or fairley water soluble drugs include: albendazole alfaxalone, acyclovir, alprostadil, aminofostin, anipamil, azido thymidine, beciomethasone, belomycin, bromocriptine, busulfan, captopril, carbamazepine, cefalexin, cefluoroxime, clonidine, corticosterone, Cortisol, cyclophosphamide, cyclosporin A, and other cyclosporins, desogestrel, dexarnethasone, dideoxyadenosine, doxorubicin, econazole, epoprostenol, estradiol, etoposide, felbamate, glipizide, griseofulvin, ketoconazole, metronidazole, nifedipine, oxytetracycline, piroxicam, prednisone, progesterone, taxol, taxotere, testosterone, vitamin A, and vitamin E succinate.
The compositions of the present invention comprise from about 15% to about 90% by weight of a liquid volume reduction agent. The active agent is initially presented in a
liquid as dispersion. The dispersion may include a suspension or a solution and the like. The liquid may be any pharmaceutically acceptable liquid such as water, alcohol, propylene glycol, glycerin, polyethylene glycol, sorbitol, among others. The liquid volume reduction agent operates to reduce the volume of the liquid dispersion comprising the active agent thereby providing a semi-solid viscous dispersion which is further processed into a solid oral rapidly disintegrating dosage form for administration. In some aspects, the amount of the liquid volume reduction agent may range from: about 10% to about 20%; about 15% to about 30%; about 15% to about 40%; about 20% to about 40%; about 15% to about 50%; about 15% to about 60%; about 15% to about 70%; about 15% to about 80%; about 20% to about 50%; about 20% to about 60%; about 20% to about
70%; about 20% to about 80%; about 20% to about 90%; about 30% to about 40%; about 30% to about 50%; about 30% to about 60%; about 30% to about 70% about 30% to about 80%; about 30% to about 90%.
The liquid volume reduction agent is any material that reduces the volume of the liquid in the liquid dispersion comprising the active agent. Some non-limiting examples include: methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, silicon dioxide, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and the like. Other examples include: polyethylene glycol,polyoxyethylene, carbomers and cellulose-based polymers, crospovidone, silicified microcrystalline cellulose, mannitol, croscarmellose, microcrystalline cellulose, calcium silicate, calcium salts such as calcium phosphate, calcium carbonate, calcium magnesium trisilicate, calcium aluminum silicate, etc.
The liquid dispersion may originally contain for example solids of about 10% or 20% or 30% or 50% or 60% or 70% or 80%. This dispersion is then contacted with a liquid volume reduction agent which facilitates the formation of a semi-solid composition by reducing the weight percentage or volume of the liquid phase. The liquid volume reduction agent for example may reduce the liquid phase of the composition by about 10%, or 20%, or 30%, or 40% or 50% or 60% or 70% or 80% or 90% either by weight or by volume. This semi-solid composition is then subjected to processes described herein such as fluid bed drying, spray congealing, fluid bed granulation, high shear granulation or forming into a suitable dosage form. One of skill in the art is knowledgeable of these processes. See for example, Remington: The Science and Practice of Pharmacy, 19th
Edition, Chapter 92 (1995); US Patent 5392531 , WO96/09814, which are incorporated by reference herein.
Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients. Such excipients are known in the art.
The active agent composition can be present in the rapidly disintegrating formulations of the invention in an amount of about 0.1% to about 99.9/(w/w), preferably about 5% to about 70% (w/w), and most preferably about 15% to about 40% (w/w), based on the total weight of the dry composition.
A rapidly disintegrating solid oral dosage form of the invention can be prepared by granulating in a fluidized bed an admixture comprising a liquid dispersion of active agent and at least one liquid volume reduction agent and optionally suitable excipients to form a granulate. This is followed by tableting of the granulate to form a solid oral dosage form.
Granulation of the composition can be accomplished using a fluid bed granulator or by using high shear granulation. Fluid bed drying can also be used in making dry powder for processing into a dosage formulation.
Powders for tableting can be formulated into tablets by any method known in the art. Suitable methods include, but are not limited to, milling, fluid bed granulation, dry granulation, direct compression, spheronization, spray congealing, and spray-dying. In an exemplary process, a rapidly disintegrating dosage form can be prepared by blending a nanoparticulate composition, comprising a poorly soluble active agent and at least one surface stabilizer, with at least one pharmaceutically acceptable water-soluble or water- dispersible excipient, and, optionally, other excipients to form a blend which is then directly compressed into tablets. For example, spray-dried nanoparticulate powder can be blended with tablet excipients using a V -blender, or high-shear mixer, followed by compression of the powder using, for example, an automated press, single station Korsch press, or a high-speed Fette tablet press. In one specific aspect, the rapidly disintegrating compositions of the present invention comprise an active agent whose particle size has remained substantially the same as compared to the particle size of the active agent in the liquid dispersion prior to
the addition of liquid volume reduction agent in the manufacturing process. Thus, the rapidly disintegrating compositions of the present invention comprise active agent whose particle size is substantially preserved in the final dosage form. As used herein, the phrases "substantially preserved" or "remained substantially the same" refer to the situation in which the particle size distribution remains within a 10-20% deviation.
Generally, the particle size distribution is measured and or represented as a mean particle diameter of a certain % of the particles. For example, it is customary in the art to designate particle size distribution as D90 of 10 microns, which represents that 90% of the particles have a mean particle diameter of 10 microns or less. Substantial preservation of particle size in the composition is significant because particle size of the active agent plays a critical role for many pharmaceutical products. For example, particle size changes may affect flow properties, dissolution, and absorption among others.
Alternatively, the present invention provides a method to prepare a rapidly disintegrating composition of an active agent without substantially changing the particle size of the active agent comprising the steps of: a) preparing a liquid dispersion of said active agent; b) adding at least one pharmaceutically acceptable liquid volume reduction agent to said liquid dispersion; c) forming a semi-solid viscous composition; and d) forming rapidly disintegrating particles; and e) optionally compressing said particles into a rapidly disintegrating tablet. In one aspect, the rapidly disintegrating particles are formed from the semi-solid viscous composition by way of freeze-drying. The technique for freeze-drying is generally known in the art. In an alternate aspect, the particles may be formed by vaccum drying. However, vaccum drying and freeze-drying techniques should be employed where no damage to or degradation of the active agent is known to occur. Another possible technique is by way of filtration. Commonly used filtering materials may be employed. Again, in all these cases, particle size of the active agent is substantially preserved.
The rapidly disintegrating solid formulations of the invention can be in the form of tablets for oral administration. Preparation of such tablets can be by pharmaceutical compression or molding techniques known in the art. The tablets of the invention may take any appropriate shape, such as discoid, round, oval, oblong, cylindrical, triangular, hexagonal, and the like. The tablets may be coated or uncoated. If coated they may be
sugar-coated (to cover objectionable tastes or odors and to protect against oxidation) or film coated (a thin film of water soluble matter for similar purposes).
In one specific aspect, the rapidly disintegrating formulations of the invention can be prepared without using a lubricating agent in a substantial amount. For example, the rapidly disintegrating tablets may be prepared wherein commonly used lubricants such as magnesium stearate are not substantially present or needed. As used herein, the term "substantially" means "to be effective." For example, as used in the context of lubricating agents, the rapidly disintegrating tablets of the present invention may be prepared wherein a lubricating agent such as magnesium stearate is either not present or if present is not in an amount to be effective to perform its intended function.
The present invention provides a method of treating a mammal including a human, requiring the rapid availability of an active ingredient. The administered rapidly disintegrating compositions of the invention rapidly release an incorporated active agent resulting in fast onset of activity. In general the compositions of the invention will be administered orally to a mammalian subject in need thereof using a level of drug or active agent that is sufficient to provide the desired physiological effect. The mammalian subject may be a domestic animal or pet but preferably is a human subject. The level of drug or active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts.
The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to a publicly available documents are specifically incorporated into this patent application by reference.
EXAMPLE 1: Preparation of a rapidly disintegrating dosage form of Drug A.
Drug A is a poorly soluble steroidal active agent. Crospovidone, mannitol and silicon dioxide each of approximately 14% by weight are used as liquid volume reduction agent. These are blended in a double cone blender until the mixture is uniform. Drug A is suspended in water at 28% w/w. The liquid volume reduction agent mixture is then slowly added to the Drug A suspension under continuous low shear mixing to form
viscous semi-solid composition. The material is then cooled to about -50 0C for about an hour. The material is then dried in a freeze drier for about 5-6 hours. Then the material is slowly brought to room temperature. This formed material is then collected in blister packs. The formulation disintegrates in about 40 seconds. The disintegration time is measured using both conventional USP apparatus and also using a stop watch and visual observation.
EXAMPLE 2
The semi-solid material as described in Example 1 is prepared. The material is then dried as in Example 1. The dried material is then sieved using a sieve of desired size (size #16). The dried sieved material iss then compressed into rapidly disintegrating tablets. The tablets disintegrate in about 30 seconds.
EXAMPLE 3 The Example 2 above is followed to prepare dried sieved materials. The material is compressed into rapidly disintegrating tablets, but this time without using any lubricating material. The tablets disintegrate in less than 20 seconds.
EXAMPLE 4 The procedure described in Example 1 is followed with the exception that crospovidone at 15% w/w is used as the liquid volume reduction agent. The formed material disintegrates in about 20 seconds.
EXAMPLE 5 The Example 2 procedure is followed except that microcrystalline cellulose (about
20%) and mannitol granules (about 40%) are used in preparing granules. Crospovidone (about 6%) is used as a disintegrant. The compressed tablet disintegrates in about 35 seconds.
EXAMPLE 6
Example 1 is followed except that croscarmellose sodium (about 5%) and silicified MCC (about 21%) are used as liquid volume reduction agents. The formed composition disintegrates in about 25 seconds.
EXAMPLE 7
Example 6 composition is used to granulate, using mannitol about 57% as flowability agent and/or disintegrant. The compressed tablet disintegrates in about 40 seconds.
EXAMPLE 8
Example 1 procedure is followed, except that the mixture of croscarmellose sodium (about 5%), silicified CMC (about 10%) and mannitol (about 10%) is used as liquid volume reduction agent. The formed product disintegrates in about 20 seconds.
EXAMPLE 9
Example 8 material is used further to granulate using about 56% of mannitol as the flowability agent/disintegrant. The compressed tablet disintegrates in about 30 seconds.
EXAMPLE 10
For the disintegration determination, a disintegration tester containing 710 micron sieves is used to test tablets in a 1000 ml deionized water bath at 37 C. Disintegration measurements are performed in accordance with USP 20.
EXAMPLE 11
The methodology of Example 1 is used to prepare rapidly disintegrating itraconazole preparation. Further, itraconazole is prepared into rapidly disintegrating tablets of 50mg, lOOmg, 200mg and 400mg per unit dose.
EXAMPLE 12
The methodology of Example 6 is used to prepare rapidly disintegrating paclitaxel preparation. Paclitaxel is prepared into tablets of lOmg, 20mg, 50mg, lOOmg and 200mg.
EXAMPLE 13
The methodology of Example 1 is used to prepare rapidly disintegrating dexamethasone preparation. Further, dexamethasone is prepared into rapidly disintegrating tablets of lmg, 2mg, 5mg, 10mg, 25mg and 50mg per unit dose.
EXAMPLE 14
The methodology of Example 7 is used to prepare rapidly disintegrating acyclovir preparation. Further, acyclovir is prepared into rapidly disintegrating tablets of 50mg, lOOmg, 200mg and 400mg per unit dose.
Of course, it is to be understood that the above-described arrangements are only illustrative of the application of the principles of the present invention. Numerous modifications and alternative arrangements may be devised by those skilled in the art without departing from the spirit and scope of the present invention and the appended claims are intended to cover such modifications and arrangements. Thus, while the present invention has been described above with particularity and detail in connection with what is presently deemed to be the most practical and preferred embodiments of the invention, it will be apparent to those of ordinary skill in the art that numerous modifications, including, but not limited to, variations in size, materials, shape, form, function and manner of operation, assembly and use may be made without departing from the principles and concepts set forth herein.
Claims
1. A method for preparing a solid dose rapidly disintegrating composition having a pharmaceutically active agent in a therapeutically effective amount, and a liquid volume reduction agent comprising from about 10% to about 90% by weight, said composition substantially completely disintegrating upon contact with a biological medium in less than about one minute, comprising: providing a liquid dispersion of an active agent; adding at least one pharmaceutically acceptable liquid volume reduction agent; forming a semi-solid viscous composition; and forming the viscous composition into rapidly disintegrating grannules that include active agent particles of about the same size as active agent particles in the liquid dispersion.
2. The method of claim 1, wherein the liquid volume reduction agent comprises from about 20% to about 90% by weight.
3. The method of claim 1, wherein the liquid volume reduction agent comprises from about 30% to about 80% by weight.
4. The method of claim 1, wherein the liquid volume reduction agent comprises from about 40% to about 90% by weight.
5. The method of claim 1, wherein the composition substantially completely disintegrates upon contact with saliva in less than about 40 seconds.
6. The method of claim I5 wherein the composition substantially completely disintegrates upon contact with saliva in less than about 20 seconds.
7. The method of claim I5 wherein the composition substantially completely disintegrates upon contact with saliva in less than about 10 seconds.
8. The method of claim 1, wherein the active agent is selected from the group consisting of: a cardiovascular drug, a psychotropic drug, an antibiotic, an antiviral agent, an analgesic, an anti-inflammatory agent, a hormone, a respiratory agent, a gastrointestinal drug.
9. The method of claim 1 , wherein liquid volume reduction agent is selected from the group consisting of a sugar, a carbomer, a cellulose-based polymer, polyethylene glycol, polyvinylpyrrolidone, polyvinylalcohol, polyoxyethylene copolymers, polyoxypropylene copolymers, polyethyleneoxide, and a mixture thereof.
10. The method of claim 1 , wherein the composition is further processed into a dosage form selected from the group consisting of: a directly compressed tablet; a granulated and compressed tablet; a sachet; and a formed dosage form.
11. The method of either of claims 1 or 2, wherein the composition is made by fluid bed granulation, spray drying, or high shear granulation.
12. The method of either of claims 1 or 2, wherein the active agent is in the form of crystalline particles, semi-crystalline particles, amorphous particles, or a mixture thereof.
13. The method of claim 2, further comprising adding one or more additional pharmaceutically acceptable excipients to the granules formed followed by compressing the granules to form a solid dose composition.
14. The method of claim 1 , wherein the active agent is a poorly soluble drug.
15. The method of claim 1 , wherein the active is a fairly soluble drug.
16. The method of claim 1, wherein said forming of rapidly disintegrating particles is achieved by subjecting the semi-solid viscous composition to a process selected from the group consisting of: fluid bed drying, freeze-drying; vaccum drying, spray congealing, and filtration.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74484506P | 2006-04-14 | 2006-04-14 | |
US60/744,845 | 2006-04-14 | ||
US11/787,115 | 2007-04-12 | ||
US11/787,115 US20070243248A1 (en) | 2006-04-14 | 2007-04-12 | Rapidly disintegrating solid oral dosage form of liquid dispersions |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007120838A2 true WO2007120838A2 (en) | 2007-10-25 |
WO2007120838A3 WO2007120838A3 (en) | 2008-12-04 |
Family
ID=38605104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/009159 WO2007120838A2 (en) | 2006-04-14 | 2007-04-13 | Rapidly disintegrating solid oral dosage form of liquid dispersions |
Country Status (2)
Country | Link |
---|---|
US (1) | US20070243248A1 (en) |
WO (1) | WO2007120838A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080069889A1 (en) * | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
JP5535616B2 (en) * | 2006-03-31 | 2014-07-02 | ルビコン リサーチ プライベート リミテッド | Direct compressible composite for orally disintegrating tablets |
WO2007130373A2 (en) * | 2006-05-01 | 2007-11-15 | Capricorn Pharma, Inc. | Novel triptan formulations and methods for making them |
US20080081072A1 (en) * | 2006-09-30 | 2008-04-03 | Cherukuri S R | Resin-complex granulation for water-soluble drugs and associated methods |
EP2101738A2 (en) * | 2006-12-21 | 2009-09-23 | Mallinckrodt Inc. | Composition of and method for preparing orally disintegrating tablets |
US20110117193A1 (en) * | 2008-01-17 | 2011-05-19 | Duquesne University Of The Holy Spirit | Antiretroviral drug formulations for treatment of children exposed to hiv/aids |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017598A (en) * | 1974-04-27 | 1977-04-12 | Shin-Etsu Chemical Company Limited | Preparation of readily disintegrable tablets |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3686000A (en) * | 1971-01-11 | 1972-08-22 | Gen Foods Corp | Moisture resistant sugar filaments |
US4327077A (en) * | 1981-05-29 | 1982-04-27 | Life Savers, Inc. | Compressed chewable antacid tablet and method for forming same |
US4497832A (en) * | 1983-04-18 | 1985-02-05 | Warner-Lambert Company | Chewing gum composition having enhanced flavor-sweetness |
US4490395A (en) * | 1983-04-18 | 1984-12-25 | Warner-Lambert Company | Chewing gum with improved stability |
US4971787A (en) * | 1984-08-27 | 1990-11-20 | Warner-Lambert Company | Antacid chewing gum |
US4642903A (en) * | 1985-03-26 | 1987-02-17 | R. P. Scherer Corporation | Freeze-dried foam dosage form |
US4915958A (en) * | 1986-12-10 | 1990-04-10 | Warner-Lambert Company | High-base gum composition with extended flavor release |
US4933190A (en) * | 1986-12-23 | 1990-06-12 | Warner-Lambert Co. | Multiple encapsulated sweetener delivery system |
US4981698A (en) * | 1986-12-23 | 1991-01-01 | Warner-Lambert Co. | Multiple encapsulated sweetener delivery system and method of preparation |
US5004595A (en) * | 1986-12-23 | 1991-04-02 | Warner-Lambert Company | Multiple encapsulated flavor delivery system and method of preparation |
IT8867588A0 (en) * | 1988-06-23 | 1988-06-23 | Aldo Venturini | DISPOSABLE SAFETY SYRINGE |
US5013716A (en) * | 1988-10-28 | 1991-05-07 | Warner-Lambert Company | Unpleasant taste masking compositions and methods for preparing same |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5219574A (en) * | 1989-09-15 | 1993-06-15 | Cima Labs. Inc. | Magnesium carbonate and oil tableting aid and flavoring additive |
US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
US5464632C1 (en) * | 1991-07-22 | 2001-02-20 | Prographarm Lab | Rapidly disintegratable multiparticular tablet |
JP2553400Y2 (en) * | 1992-01-22 | 1997-11-05 | 日立金属株式会社 | Developing device |
US5466646A (en) * | 1992-08-18 | 1995-11-14 | Worcester Polytechnic Institute | Process for the preparation of solid state materials and said materials |
US5503846A (en) * | 1993-03-17 | 1996-04-02 | Cima Labs, Inc. | Base coated acid particles and effervescent formulation incorporating same |
WO1995001782A2 (en) * | 1993-07-09 | 1995-01-19 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5851553A (en) * | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
US5635210A (en) * | 1994-02-03 | 1997-06-03 | The Board Of Regents Of The University Of Oklahoma | Method of making a rapidly dissolving tablet |
JP2977907B2 (en) * | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | Controlled release dosage form of azithromycin |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5582855A (en) * | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5556652A (en) * | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
GB9421836D0 (en) * | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5807578A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US5807577A (en) * | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
US5709866A (en) * | 1996-12-05 | 1998-01-20 | Sage Products, Inc. | Dual bag mouth care package |
US5869098A (en) * | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US6365209B2 (en) * | 2000-06-06 | 2002-04-02 | Capricorn Pharma, Inc. | Confectionery compositions and methods of making |
US20070059367A1 (en) * | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
US7678387B2 (en) * | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
US6555145B1 (en) * | 2000-06-06 | 2003-04-29 | Capricorn Pharma, Inc. | Alternate encapsulation process and products produced therefrom |
US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
US20030096001A1 (en) * | 2000-06-06 | 2003-05-22 | Cherukuri S. Rao | Encapsulation products and method of controlled release of fluoxetine or mesalamine |
US20100010101A1 (en) * | 2000-07-05 | 2010-01-14 | Capricorn Pharma, Inc. | Rapid-Melt Compositions and Methods of Making Same |
US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
WO2002002081A1 (en) * | 2000-07-05 | 2002-01-10 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and methods of using same |
US20020197323A1 (en) * | 2001-06-22 | 2002-12-26 | Cherukuri Subraman Rao | Stable solid delivery system and method of preparing same |
US20070059368A1 (en) * | 2005-05-31 | 2007-03-15 | Cherukuri S R | Modified release formulations of anti-irritability drugs |
US20030026826A1 (en) * | 2001-07-31 | 2003-02-06 | Cherukuri Subraman Rao | Sugar-free chewy products and protein-based chewy products and methods for making the same |
US20070082050A1 (en) * | 2005-05-31 | 2007-04-12 | Cherukuri S R | Modified release formulations of antihypertensive drugs |
US20090017110A1 (en) * | 2005-05-31 | 2009-01-15 | Capricorn Pharma Inc. | Modified release formulations of anti-irritability drugs |
US20080085318A1 (en) * | 2005-07-16 | 2008-04-10 | Cherukuri S R | Coated compositions and methods for preparing same |
US20070212417A1 (en) * | 2006-03-07 | 2007-09-13 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
US20080069889A1 (en) * | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
WO2007130373A2 (en) * | 2006-05-01 | 2007-11-15 | Capricorn Pharma, Inc. | Novel triptan formulations and methods for making them |
US8202538B2 (en) * | 2006-06-26 | 2012-06-19 | Capricorn Pharma, Inc. | Orally disintegrating layered compositions |
WO2008005318A2 (en) * | 2006-06-29 | 2008-01-10 | Capricorn Pharma Inc. | Chewy products and methods for making the same |
US20080081072A1 (en) * | 2006-09-30 | 2008-04-03 | Cherukuri S R | Resin-complex granulation for water-soluble drugs and associated methods |
US20090136550A1 (en) * | 2007-11-16 | 2009-05-28 | Capricorn Pharma Inc. | Modified release formulations of diltiazem |
WO2009067684A1 (en) * | 2007-11-21 | 2009-05-28 | Capricorn Pharma Inc. | Modified release niacin formulations |
WO2009140557A2 (en) * | 2008-05-14 | 2009-11-19 | Capricorn Pharma, Inc. | Modified release tolterodine formulations |
WO2009140527A1 (en) * | 2008-05-14 | 2009-11-19 | Capricorn Pharma, Inc. | Modified release formulations of dihydropyridine compounds and methods of making same |
-
2007
- 2007-04-12 US US11/787,115 patent/US20070243248A1/en not_active Abandoned
- 2007-04-13 WO PCT/US2007/009159 patent/WO2007120838A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4017598A (en) * | 1974-04-27 | 1977-04-12 | Shin-Etsu Chemical Company Limited | Preparation of readily disintegrable tablets |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
Also Published As
Publication number | Publication date |
---|---|
WO2007120838A3 (en) | 2008-12-04 |
US20070243248A1 (en) | 2007-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1282399B1 (en) | Rapidly disintegrating solid oral dosage form | |
JP2955524B2 (en) | Solid drug preparation | |
JP5346021B2 (en) | Orally disintegrating tablet composition of lamotrigine | |
JP5537943B2 (en) | Fast disintegrating solid preparation | |
JP5908505B2 (en) | Deferasirox dispersible tablets | |
US20090130213A1 (en) | Rapidly disintegrating solid oral dosage form | |
JP2017075182A (en) | Composition having combination of immediate release and controlled release properties | |
EP2590630B1 (en) | Oral dosage form of deferasirox | |
US20130095177A1 (en) | Method of preparing an oral dosage form comprising fingolimod | |
JP5763063B2 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic use | |
WO2010078429A1 (en) | Pharmaceutical dosage forms and methods of manufacturing same | |
CA2923055C (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
US20070243248A1 (en) | Rapidly disintegrating solid oral dosage form of liquid dispersions | |
JP2010536798A (en) | Method and composition for controlling bioavailability of poorly soluble drugs | |
WO2008037044A1 (en) | Oxcarbazepine-containing oral formulation and a process to obtain the same | |
EP2471520B1 (en) | Pharmaceutical compositions of levetiracetam | |
US20130165459A1 (en) | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof | |
WO2000032166A2 (en) | Microparticles containing water insoluble active agents | |
JP2023535829A (en) | Pharmaceutical composition containing coated API | |
CN117836275A (en) | Dedostat particles and compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07755432 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07755432 Country of ref document: EP Kind code of ref document: A2 |